amantadine has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 38 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Potential neuroprotective activity of the novel antiparkinsonian drug hemantane (hydrochloride N-2-(adamantyl)-hexamethylenimine) in comparison to amantadine has been studied in various regimes of administration on human neuroblastoma SH-SY5Y cell line injury induced by 6-hydroxydopamine (6-OHDA), which is used as in vitro model of dopaminergic neurons for Parkinson's disease." | 7.83 | [COMPARISON OF CYTOPROTECTIVE EFFECTS OF HEMANTANE AND AMANTADINE UNDER CONDITIONS OF 6-HYDROXYDOPAMINE NEUROTOXIN ACTION ON CULTURED HUMAN NEUROBLASTOMA CELLS]. ( Antipova, TA; Logvinov, IO; Nepoklonov, AV; Valdman, EA, 2016) |
| "Potential neuroprotective activity of the novel antiparkinsonian drug hemantane (hydrochloride N-2-(adamantyl)-hexamethylenimine) in comparison to amantadine has been studied in various regimes of administration on human neuroblastoma SH-SY5Y cell line injury induced by 6-hydroxydopamine (6-OHDA), which is used as in vitro model of dopaminergic neurons for Parkinson's disease." | 3.83 | [COMPARISON OF CYTOPROTECTIVE EFFECTS OF HEMANTANE AND AMANTADINE UNDER CONDITIONS OF 6-HYDROXYDOPAMINE NEUROTOXIN ACTION ON CULTURED HUMAN NEUROBLASTOMA CELLS]. ( Antipova, TA; Logvinov, IO; Nepoklonov, AV; Valdman, EA, 2016) |
| "Amantadine is an antiparkinsonian medication scarcely associated with PHS." | 2.72 | Parkinsonism-hyperpyrexia Syndrome After Amantadine Withdrawal: Case Report and Review of the Literature. ( Dos Santos, DT; Imthon, AK; Pille, A; Schumacher-Schuh, AF; Strelow, MZ, 2021) |
| "Our patient had developed overt parkinsonism presenting with a resting tremor, expressionless face, and lack of blinking along with marked cogwheel rigidity and a stooped, slow gait." | 2.43 | Extrapyramidal parkinsonism complicating acute organophosphate insecticide poisoning. ( Bar-Joseph, G; Bentur, Y; Cahana, A; Hershman, E; Shahar, E, 2005) |
| "There are many causes of parkinsonism such as drug induced parkinsonism, subcortical vascular disease, and multisystem atrophy." | 2.42 | [Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?]. ( Ceballos-Baumann, A, 2003) |
| "Dopamine replacement therapy using L-3,4-dihydroxyphenylalanine (L-DOPA) is a gold standard treatment in patients with Parkinson's disease (PD); however, chronic administration of L-DOPA causes excessive involuntary movements called L-DOPA-induced dyskinesia." | 1.56 | Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats. ( Arakawa, K; Maehara, S; Yuge, N, 2020) |
| "Amantadine (10 mg/kg PO) was tested as a positive control." | 1.56 | The selective 5-HT ( Brotchie, JM; Depoortere, R; Fox, SH; Johnston, TH; Newman-Tancredi, A, 2020) |
| "Amantadine may cause RVOT-VT as well as other cardiac arrhythmias." | 1.42 | Right ventricular outflow tract tachycardia after an initial dose of amantadine. ( Çetinkal, G; Doğan, SM; Kocaş, C; Türkmen, Y, 2015) |
| "Although neurological manifestations of typhoid fever was thought to be obsolete from modern world, emergence of multidrug resistant typhoid bacilli and reporting of outbreak of typhoid fever with a range of early neuropsychiatric manifestations from various parts of world has led clinicians and investigators to re-evaluate the clinical spectrum of this endemic sinister disease." | 1.39 | Catatonia and parkinsonism as a sequelae of typhoid fever: a rare experience. ( Dutta, A; Rana, S; Talukdar, A; Talukdar, P, 2013) |
| " The chronic administration of these drugs together with amantadine (20 mg/kg) accelerates the onset of latency and increases the magnitude of dyskinesia." | 1.37 | [Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome]. ( Ivanova, EA; Kapitsa, IG; Kokshenev, II; Nepoklonov, AV; Val'dman, EA; Voronina, TA, 2011) |
| "Methanol poisoning is an uncommon but potent central nervous system toxin." | 1.32 | Methanol poisoning: diagnosis and management. A case report. ( Ahmed, S; Ashebu, SD; Bitar, ZI, 2004) |
| "Once a parkinsonian syndrome was diagnosed, she was given amantadine therapy with complete recovery." | 1.31 | Extra-pyramidal parkinsonism complicating organophosphate insecticide poisoning. ( Andraws, J; Shahar, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.63) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (31.58) | 29.6817 |
| 2010's | 17 (44.74) | 24.3611 |
| 2020's | 8 (21.05) | 2.80 |
| Authors | Studies |
|---|---|
| Bourque, M | 3 |
| Grégoire, L | 3 |
| Patel, W | 3 |
| Dickens, D | 3 |
| Snodgrass, R | 3 |
| Di Paolo, T | 3 |
| Rentsch, P | 1 |
| Stayte, S | 1 |
| Egan, T | 1 |
| Clark, I | 1 |
| Vissel, B | 1 |
| Arakawa, K | 1 |
| Yuge, N | 1 |
| Maehara, S | 1 |
| Shen, W | 1 |
| Ren, W | 1 |
| Zhai, S | 1 |
| Yang, B | 1 |
| Vanoye, CG | 1 |
| Mitra, A | 1 |
| George, AL | 1 |
| Surmeier, DJ | 1 |
| Wiwanitkit, V | 1 |
| Aranda-Abreu, GE | 1 |
| Depoortere, R | 1 |
| Johnston, TH | 2 |
| Fox, SH | 2 |
| Brotchie, JM | 2 |
| Newman-Tancredi, A | 1 |
| Dos Santos, DT | 1 |
| Imthon, AK | 1 |
| Strelow, MZ | 1 |
| Pille, A | 1 |
| Schumacher-Schuh, AF | 1 |
| McGarry, A | 1 |
| Biglan, K | 1 |
| Talukdar, P | 1 |
| Dutta, A | 1 |
| Rana, S | 1 |
| Talukdar, A | 1 |
| Kocaş, C | 1 |
| Türkmen, Y | 1 |
| Çetinkal, G | 1 |
| Doğan, SM | 1 |
| Chattopadhyaya, I | 1 |
| Gupta, S | 1 |
| Mohammed, A | 1 |
| Mushtaq, N | 1 |
| Chauhan, S | 1 |
| Ghosh, S | 2 |
| Park, H | 1 |
| Jeon, BS | 1 |
| Shin, JH | 1 |
| Park, SH | 1 |
| Zhang, LL | 1 |
| Canning, SD | 1 |
| Wang, XP | 1 |
| Tada, H | 1 |
| Ogihara, T | 1 |
| Nakamura, T | 1 |
| Sasayama, D | 1 |
| Sugiyama, N | 1 |
| Takahashi, Y | 1 |
| Washizuka, S | 1 |
| Amano, N | 1 |
| Logvinov, IO | 2 |
| Antipova, TA | 2 |
| Nepoklonov, AV | 2 |
| Valdman, EA | 1 |
| Ghaffariyeh, A | 1 |
| Honarpisheh, N | 1 |
| Spinnewyn, B | 1 |
| Charnet, C | 1 |
| Cornet, S | 1 |
| Roubert, V | 1 |
| Chabrier, PE | 1 |
| Auguet, M | 1 |
| Zimin, IA | 1 |
| Kovalev, GI | 1 |
| Ossola, B | 1 |
| Schendzielorz, N | 1 |
| Chen, SH | 1 |
| Bird, GS | 1 |
| Tuominen, RK | 1 |
| Männistö, PT | 1 |
| Hong, JS | 1 |
| Kapitsa, IG | 1 |
| Ivanova, EA | 1 |
| Kokshenev, II | 1 |
| Voronina, TA | 1 |
| Val'dman, EA | 1 |
| Paquette, MA | 1 |
| Martinez, AA | 1 |
| Macheda, T | 1 |
| Meshul, CK | 1 |
| Johnson, SW | 1 |
| Berger, SP | 1 |
| Giuffrida, A | 1 |
| Breger, LS | 1 |
| Dunnett, SB | 1 |
| Lane, EL | 1 |
| Yeh, CH | 1 |
| Lin, SF | 1 |
| Lin, CY | 1 |
| Chen, CY | 1 |
| Chow, KC | 1 |
| Bezard, E | 1 |
| Tronci, E | 1 |
| Pioli, EY | 1 |
| Li, Q | 1 |
| Porras, G | 1 |
| Björklund, A | 1 |
| Carta, M | 2 |
| Skolimowski, J | 1 |
| Kochman, A | 1 |
| Gebicka, L | 1 |
| Metodiewa, D | 1 |
| Ceballos-Baumann, A | 1 |
| Bitar, ZI | 1 |
| Ashebu, SD | 1 |
| Ahmed, S | 1 |
| Lundblad, M | 1 |
| Usiello, A | 1 |
| Håkansson, K | 1 |
| Fisone, G | 1 |
| Cenci, MA | 1 |
| Shahar, E | 2 |
| Bentur, Y | 1 |
| Bar-Joseph, G | 1 |
| Cahana, A | 1 |
| Hershman, E | 1 |
| Visanji, NP | 1 |
| Gomez-Ramirez, J | 1 |
| Pires, D | 1 |
| Voon, V | 1 |
| Fann, WE | 1 |
| Lake, CR | 1 |
| Shiio, Y | 1 |
| Fredriksson, A | 1 |
| Danysz, W | 1 |
| Quack, G | 1 |
| Archer, T | 1 |
| Andraws, J | 1 |
| Brooks, DJ | 1 |
| Finsterer, J | 1 |
6 reviews available for amantadine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Parkinsonism-hyperpyrexia Syndrome After Amantadine Withdrawal: Case Report and Review of the Literature.
Topics: Aged; Amantadine; Antiparkinson Agents; Female; Humans; Neuroleptic Malignant Syndrome; Parkinson Di | 2021 |
Freezing of Gait in Parkinsonism and its Potential Drug Treatment.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Botulinum Toxins; Droxidopa; Gait Disorde | 2016 |
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].
Topics: Aged; Amantadine; Antiparkinson Agents; Apomorphine; Botulinum Toxins; Catechols; Cholinesterase Inh | 2003 |
Extrapyramidal parkinsonism complicating acute organophosphate insecticide poisoning.
Topics: Acute Disease; Adolescent; Amantadine; Antiparkinson Agents; Basal Ganglia Diseases; Dimethoate; Hum | 2005 |
[Drug-induced parkinsonism].
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Benzamides; Butyrophenones; Calcium Channel | 2007 |
[Parkinson disease: diagnostic and therapeutic criteria].
Topics: Activities of Daily Living; Adult; Aged; Amantadine; Antiparkinson Agents; Bromocriptine; Diagnosis, | 2001 |
1 trial available for amantadine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
On the coexistence of parkinsonism and tardive dyskinesia.
Topics: Amantadine; Antiparkinson Agents; Cross-Over Studies; Double-Blind Method; Dyskinesia, Drug-Induced; | 1974 |
31 other studies available for amantadine and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
Targeting the cannabinoid receptor CB2 in a mouse model of l-dopa induced dyskinesia.
Topics: Amantadine; Animals; Antiparkinson Agents; Camphanes; Cannabinoid Receptor Agonists; Cannabinoids; D | 2020 |
Ameliorative effects of a phosphodiesterase 10A inhibitor, MR1916 on L-DOPA-induced dyskinesia in parkinsonian rats.
Topics: Administration, Oral; Amantadine; Animals; Antiparkinson Agents; Dose-Response Relationship, Drug; D | 2020 |
Striatal Kir2 K+ channel inhibition mediates the antidyskinetic effects of amantadine.
Topics: Amantadine; Animals; Antiparkinson Agents; CHO Cells; Corpus Striatum; Cricetulus; Dyskinesia, Drug- | 2020 |
Amantadine, COVID-19 and Parkinsonism.
Topics: Amantadine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Parkinsonian Disor | 2020 |
Response to: Amantadine, COVID-19 and Parkinsonism.
Topics: Amantadine; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Parkinsonian Disor | 2020 |
The selective 5-HT
Topics: Amantadine; Animals; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Levo | 2020 |
Improvement of freezing of gait with amantadine in a patient with oculopharyngeal muscular dystrophy and Parkinsonism.
Topics: Aged; Amantadine; Antiparkinson Agents; Freezing Reaction, Cataleptic; Gait Disorders, Neurologic; H | 2013 |
Catatonia and parkinsonism as a sequelae of typhoid fever: a rare experience.
Topics: Adolescent; Amantadine; Antiparkinson Agents; Antipsychotic Agents; Benzodiazepines; Benzothiazoles; | 2013 |
Right ventricular outflow tract tachycardia after an initial dose of amantadine.
Topics: Amantadine; Electrocardiography; Female; Heart Ventricles; Humans; Middle Aged; Parkinsonian Disorde | 2015 |
Neuroprotective effect of Spirulina fusiform and amantadine in the 6-OHDA induced Parkinsonism in rats.
Topics: Amantadine; Animals; Dietary Supplements; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorder | 2015 |
A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea.
Topics: Amantadine; Antiparkinson Agents; Benzothiazoles; Brain; Chorea; Humans; Levodopa; Male; Middle Aged | 2016 |
A case of severe parkinsonism in an elderly person induced by valproic acid.
Topics: Aged; Amantadine; Anticonvulsants; Brain; Dose-Response Relationship, Drug; Female; Humans; Magnetic | 2017 |
[COMPARISON OF CYTOPROTECTIVE EFFECTS OF HEMANTANE AND AMANTADINE UNDER CONDITIONS OF 6-HYDROXYDOPAMINE NEUROTOXIN ACTION ON CULTURED HUMAN NEUROBLASTOMA CELLS].
Topics: Adamantane; Amantadine; Cell Line, Tumor; Cytoprotection; Dose-Response Relationship, Drug; Humans; | 2016 |
Amantadine-associated corneal edema.
Topics: Aged; Amantadine; Anti-Inflammatory Agents; Antiparkinson Agents; Corneal Edema; Female; Humans; Oph | 2010 |
An improved model to investigate the efficacy of antidyskinetic agents in hemiparkinsonian rats.
Topics: Adenosine A2 Receptor Antagonists; Amantadine; Animals; Antiparkinson Agents; Behavior, Animal; Bens | 2011 |
[A comparative study of hemantane and amantadine effects on dopamine transporter expression in brain of normal and MPTP-treated C57BL/6 mice].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adamantane; Amantadine; Animals; Antiparkinson Agents; | 2011 |
Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected].
Topics: Amantadine; Animals; Animals, Newborn; Astrocytes; Cells, Cultured; Coculture Techniques; Dopamine; | 2011 |
[Comparative study of amantadine and hemantane effects on development of levodopa-induced dyskinesia in rat model of parkinsonian syndrome].
Topics: Adamantane; Amantadine; Animals; Behavior, Animal; Benserazide; Disease Models, Animal; Dyskinesia, | 2011 |
Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson's disease: role of NMDA vs. 5-HT1A receptors.
Topics: Amantadine; Animals; Antiparkinson Agents; Cycloserine; Dextromethorphan; Dopamine Agents; Dyskinesi | 2012 |
Comparison of rating scales used to evaluate L-DOPA-induced dyskinesia in the 6-OHDA lesioned rat.
Topics: Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Dopamine Agonists; Dyskinesia, Drug-In | 2013 |
Acute onset of parkinsonism with reversible course after H1N1 vaccination: insight from a young lady.
Topics: Adolescent; Amantadine; Benzothiazoles; Drug Therapy, Combination; Female; Humans; Influenza A Virus | 2012 |
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.
Topics: Amantadine; Amphetamine; Animals; Apomorphine; Disease Models, Animal; Dopamine Agents; Dyskinesia, | 2013 |
Synthesis and antioxidant activity evaluation of novel antiparkinsonian agents, aminoadamantane derivatives of nitroxyl free radical.
Topics: Adamantane; Amantadine; Animals; Antioxidants; Antiparkinson Agents; Brain; Dopamine; Female; Free R | 2003 |
Methanol poisoning: diagnosis and management. A case report.
Topics: Adult; Amantadine; Antiparkinson Agents; Humans; Male; Methanol; Parkinsonian Disorders; Solvents; T | 2004 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |
Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Apomorphine | 2006 |
Co-administration of memantine and amantadine with sub/suprathreshold doses of L-Dopa restores motor behaviour of MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dizocilpine | 2001 |
Extra-pyramidal parkinsonism complicating organophosphate insecticide poisoning.
Topics: Adolescent; Amantadine; Antiparkinson Agents; Basal Ganglia Diseases; Female; Humans; Insecticides; | 2001 |
Diagnosis and management of atypical parkinsonian syndromes.
Topics: Amantadine; Antiparkinson Agents; Brain; Cholinergic Antagonists; Diagnosis, Differential; Diagnosti | 2002 |
Parkinson syndrome as a manifestation of mitochondriopathy.
Topics: Aged; Aged, 80 and over; Amantadine; Antiparkinson Agents; Biopsy; DNA, Mitochondrial; Dopamine; Ele | 2002 |